Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real‐world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety‐two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%‐84.3%]) or persistent (median [range] 47.7% [16.9%‐94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget‐neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget‐neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784
Self-citationde Pablos‐Velasco, P., Parhofer, K. G., Bradley, C., Eschwège, E., Gönder-Frederick, L., Maheux, P., Wood, I., & Simon, D. (2014) · Clinical Endocrinology · doi:10.1111/cen.12119 · Cited by 218
Medication Nonadherence in Diabetes
Egede, L. E., Gebregziabher, M., Dismuke, C. E., Lynch, C. P., Axon, R. N., Zhao, Y., & Mauldin, P. D. (2012) · Diabetes Care · doi:10.2337/dc12-0572 · Cited by 195
Carls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153 · cited 1×
“Three studies reported persistence estimates for multiple classes of antidiabetic medication.(27,31,66) As was the case for adherence, persistence estimates varied”
BackgroundSelf-citationLongitudinal effects of medication nonadherence on glycemic control
Egede, L. E., Gebregziabher, M., Echols, C., & Lynch, C. P. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014526362 · Cited by 146
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106 · cited 1×
“Various demographic, social, and patient- and physician-related factors contribute to the likelihood of people with T2D achieving glycaemic control,(13,14) including the extent to which patients are adherent to and persistent with antidiabetic medication.(15,16) Although there is evidence that adherence and persistenc…”
BackgroundBuysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101 · cited 3×
“or a trend for better outcomes in persistent than in nonpersistent patients.(30,38,40,58,60,62,74,79,81,94,96,107,109) However, the results were more heterogeneous in the studies investigating combination therapies,(27,66,69,75,105,112) with only two studies clearly demonstrating superior glycaemic control in persiste…”
ResultMody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93 · cited 1×
“Study duration ranged from 6 months(75,107) to 3 years,(94) and was 12 months in 17 studies.(24,25,29-31,40,52,58,60,62,69,77,80,90,96,104) Overall, six studies examined persistence with OADs,(29,58,60,62,90,94) 11 studies with insulin,(24,25,40,52,61,77,89,96,104,107,109) seven studies with injectable GLP-1RAs(30,38,…”
BackgroundSvensson, E., Baggesen, L. M., Johnsen, S. P., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Thomsen, R. W. (2017) · Diabetes Care · doi:10.2337/dc16-2271 · Cited by 77
Weeda, E. R., Muraoka, A. K., Brock, M. D., & Cannon, J. M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14060 · Cited by 73
Cited by
Palanca, A., Ampudia-Blasco, F. J., Calderón, J. M., Sauri, I., Martinez-Hervás, S., Trillo, J. L., Redón, J., & Real, J. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01382-9 · Cited by 48
Song, X., Wu, J., Yang, Y., Xu, W., Shi, X., Dong, K., Li, M., Chen, X., Wang, Y., Bian, X., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092110 · Cited by 5
Ali, M., Amirthalingam, P., Alshareef, H., Alqifari, S., Elsaid Hamdan, A., Alatawi, O., Hakami, F., Albalawi, N., & Aljabri, A. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s569096 · Cited by 2
Metadata
- Authors
- Evans, M., Engberg, S., Faurby, M., Fernandes, J. D. D. R., Hudson, P., & Polonsky, W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-12-09
- Volume
- 24
- Issue
- 3
- Pages
- 377-390
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3212600493
- Cited by
- 90
- References
- 14
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. https://app.cochat.ai/papers/10.1111/dom.14603
- The paper
- Evans, M., Engberg, S., Faurby, M., Fernandes, J. D. D. R., Hudson, P., & Polonsky, W. (2022). Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.